Navigation Links
GlaxoSmithKline 14th Annual IMPACT Awards Seek Greater Philadelphia and Camden Healthcare Nonprofits
Date:2/15/2010

PHILADELPHIA, Feb. 15 /PRNewswire-FirstCall/ -- The GlaxoSmithKline (NYSE: GSK) 14th Annual IMPACT Awards target community-based nonprofits that provide access to healthcare for the underserved. Up to ten organizations in the Pennsylvania counties of Berks, Bucks, Chester, Delaware, Lancaster, Lehigh, Montgomery, and Philadelphia and the City of Camden, New Jersey, will be awarded $40,000 each. The awards are bestowed upon winning organizations for success and achievements in their current, overall work, not just for new or specific initiatives. Applications will be accepted through March 29, 2010, 4:00 p.m. EDT.

Every year the GlaxoSmithKline IMPACT Awards acknowledge, highlight and reward nonprofit organizations that have a significant impact on their communities and are accomplished, proactive and effective in their work. GlaxoSmithKline's IMPACT Awards represent and support Innovation, Management, Partnership, Achievement, Community focus and Targeting needs within community-based healthcare organizations. Nonprofits that exemplify the IMPACT Awards criteria continue to provide quality, accessible healthcare to their communities despite their financial and resource limitations. Winners in previous years include organizations that provide medical and dental care for the underserved, access to care for the chronically ill, services for children with genetic disorders and comprehensive treatment for women with addiction.

To qualify for a GlaxoSmithKline IMPACT award, applicants must provide access to healthcare services (primary mission); have annual total operating expenses between $160,000 and $3 million, as documented in the organization's most recent fiscal year financial statement; and have been in existence as a 501(c)(3) nonprofit organization for at least five years. A panel of local and national healthcare delivery experts and GlaxoSmithKline representatives will determine the winners based on a strong demonstration of ongoing success in providing access to healthcare; commitment to serving people in need; facilitation of healthcare delivery, substantive partnerships; policy development; and a solid record of achievement, management and leadership.

The GlaxoSmithKline IMPACT Awards will be presented at an awards ceremony in Philadelphia in late 2010. For more details and to apply, please visit the GlaxoSmithKline site at www.gsk-us.com and select "Our work with communities," then click "Health programs," then click "Awards," and finally click "Philadelphia region" or call GlaxoSmithKline Community Partnerships at 215-751-5171.

About GlaxoSmithKline: GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at www.gsk-us.com.

SOURCE GlaxoSmithKline

RELATED LINKS
http://www.gsk-us.com

'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... from its market value in 2016. There are currently three proton therapy ... capacity to treat more patients. In Italy , the ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Navigation Systems Market 2014 - 2025" report to their ... ... reach USD 303.7 million by 2025. Increasing geriatric population prone ... demand for orthopedic navigation systems over the forecast period. Osteoarthritis ...
Breaking Medicine Technology:
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... Dr. ... on early orthodontic treatment and accepting new pediatric patients, with or without a referral. ... young patients have a better orthodontic outcome and experience. When patients receive early treatment, ...
(Date:3/29/2017)... MINNETONKA, Minn. (PRWEB) , ... March 29, 2017 ... ... of medical office buildings (MOBs) and other outpatient facilities, and who are the ... look exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , ... announce the finalization of the company’s executive management team with prominent executives from both ... is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar — ... 1:00 PM ET. A recording of the webinar will also be made available following ... health and hospice companies are still popular targets for healthcare investors. This highly fragmented ...
Breaking Medicine News(10 mins):